1 |
Afzal MS, Ahmed T, Zaidi NU. (2014). Comparison of HCV prevalence in Pakistan and Iran; an insight into future. Hepat Mon, 14, 11466
|
2 |
Afzal MS, Anjum S, Zaidi NU. (2013) Effect of functional interleukin-10 polymorphism on pegylated interferon- plus ribavirin therapy response in chronic hepatitis c virus patients infected with 3a genotype in Pakistani Population. Hepat Mon, 13, 10274
|
3 |
Afzal MS, Anjum S, Zaidi NU. (2014). Changing of HCV clade pattern in iran; the possible means for something good. Hepat Mon, 14, 11879
|
4 |
Afzal MS, Khan MY, Ammar M et al (2014). Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem. World J Gastroenterol, 20, 17690-2
DOI
|
5 |
Afzal MS, Tahir S, Salman A, et al (2011). Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries, 5, 473-9
|
6 |
Ahmad B, Ali S, Ali I et al (2013). Conventional Interferon Therapy Response among Chronic HCV Patients in Khyber Pakhtunkhwa. J Infect Dis Ther, 1, 104.
|
7 |
Ahmad B, Ali S, Ali I, Azam S, Bashir S (2012). Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J, 9, 18.
DOI
|
8 |
Akhtar N, Bilal M, Rizwan M. et al (2015). Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district mardan, khyber pakhtunkhawa, Pakistan. Asian Pac J Cancer Prev, 16, 1037-40.
DOI
|
9 |
Amer S, Hajira A, Muqeetadnan M. (2014). The hepatitis c virus treatment revolution-can thedeveloping world afford it? J GHR, 3, 1131-2.
|
10 |
Anjum S, Afzal MS, Ahmad T, et al (2013). Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Mol Med Rep, 8, 487-92
|
11 |
Anjum S, Wahid A, Afzal MS, et al (2013). Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization. J Infect Dis, 208, 1888-97.
DOI
|
12 |
Gane ED. (2014). Hepatitis C beware-the end is nigh. Lancet, 384, 1557-60.
DOI
|
13 |
World health Organization. http://www.who.int/countries/pak/en/ data collected on 07 March 2015.
|